has acquired a 41.23 per cent stake in 7Med India Pvt Ltd and Epitome Group of Hospitals, one of India’s leading dialysis and nephrology service providers, through a binding agreement worth approximately ₹127 crores. The deal includes a contractual path to majority ownership within 12 months and potential expansion to 76 per cent stake over time.
The transaction combines primary and secondary stake purchases as PVP builds its healthcare services platform focusing on illness, wellness and care. Future investments are contingent on achieving predetermined financial benchmarks.
Delhi NCR-based 7Med operates 22 establishments including dialysis centers and four super-specialty hospitals across six states, employing over 450 professionals. The company currently generates an EBITDA of ₹10 crores and projects growth to ₹50 crores within four years. It ranks among India’s top five organized renal care players, having conducted over one million dialysis procedures.
The company was founded by healthcare veterans including Dr. Vijay Kher and Dr. Sudhanshu Tyagi, who previously held leadership positions at Fresenius Medical Care, B. Braun Medical, Medanta Group and Fortis Group.
PVP plans to use expected cash flows exceeding ₹2,000 crores from real estate developments with Brigade Enterprises and Casagrand Premier Builder to fund healthcare sector acquisitions. The investment will help 7Med expand into tier-2 and tier-3 cities across multiple states.
The were trading at ₹20.82 down by ₹0.11 or 0.53 per cent on the NSE today at the closing bell.